期刊文献+

度洛西汀与帕罗西汀治疗广泛性焦虑对照研究 被引量:4

A controlled study of duloxetine and paroxitine in the treatment of generalized anxiety disorder
暂未订购
导出
摘要 目的探讨度洛西汀与帕罗西汀治疗广泛性焦虑的临床疗效和安全性。方法将26例广泛性焦虑患者随机分为两组各13例,研究组口服度洛西汀胶囊治疗,对照组口服帕罗西汀治疗,观察6w。于治疗前及治疗2w、4w、6w末采用汉密顿焦虑量表和临床疗效总评量表的病情严重程度分量表评定临床疗效,副反应量表评定不良反应。结果两组治疗6w末总有效率均为100%。治疗1w末两组汉密顿焦虑量表总分均较治疗前有显著下降(P〈0.05或0.01),但研究组较对照组下降更显著(P〈0.05),随治疗时间的延续均呈持续性下降;两组治疗后临床疗效总评量表评分均较治疗前有显著下降(P〈0.01);两组不良反应均较轻微。结论洛西汀治疗广泛性焦虑疗效显著,与帕罗西汀相当,但起效更快,安全性高,依从性好。 ObjectiveTo explore the efficacy and safety of duloxetine and paroxetine in treatment of generalized anxiety disorder. Methods 26 patients with generalized anxiety disorder (GAD) were randomly assigned to research group(n= 13) taking orally duloxetine and control group(n= 13) doing paroxetine for 6 weeks. Curative effects were assessed with the Hamilton Anxiety Scale(HAMA) and the Clinical Global Impression(CGI) before treatment and at the ends of the 1th, 2nd,4th and 6th week treatment, adverse reactions with the Treatment Emergent Symptom Scale(TESS). Results After 6 week treatment, total effective rates of both groups were 100%. At the end of the 1st week, total scores of the HAMA of both groups lowered more significantly compared with pre-treatment(P〈0.05 or 0.01), that did more significantly in the research than in the control group(P〈0.05), and those of both groups did continously following time of therapy lasting; scores of the CGI of both groups lowered more significantly after treatment (P〈0.01) ; adverse raections of both groups were mild. Conclusion Duloxetine has evident effects equivalent to paroxetine, but takes effects more quickly and has higher safety and better compliance in the treatment of generalized anxiety disorder.
出处 《临床心身疾病杂志》 CAS 2009年第2期117-119,共3页 Journal of Clinical Psychosomatic Diseases
关键词 广泛性焦虑 度洛西汀 帕罗西汀 汉密顿焦虑量表 临床疗效总评量表 Generalized anxiety disorder duloxetine paroxetine HAMA CGI
  • 相关文献

参考文献7

  • 1Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-lind, controlled study [J]. Neuropsychopharmacology, 2003,28 (9) : 1685
  • 2Michael J, Detkea MD, Yili L, et al. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression [J]. Journal of Psychiatric Research,2003. 40:383
  • 3Michael J, Detkea MD. Duloxetine, 60mg daily, for major depressive disorder.- A randomized double-blind placebo controlled trial[J]. J Clin Psychiatry, 2003,63 : 308
  • 4David L, Dunner A, Deborahn, et al. Is treatment associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression[J]. Journal of Affective Disorders,2005,87 : 115
  • 5马闯胜,张淑芳,杨靖.帕罗西汀与阿米替林治疗躯体形式障碍对照研究[J].临床心身疾病杂志,2007,13(4):299-300. 被引量:22
  • 6Michael J, Detke, Curtis G Wihse, et al. Duloxetine in the acute and long-term treatment of major depressive disorder:a placebo and paroxetine-controlled trial[J]. Eur Neuropsychopharmacol, 2004,14 (6) : 457
  • 7Robert MA, Hirschfeld, Lana A Vrnik. Newer antide pressants: reviews of efficacy and safety of escitalopram and duloxeline[J]. J Clin Psychiatry, 2004,65 (suppl 4) : 46

二级参考文献2

  • 1沈渔邨.精神病学[M](第4版)[M].北京:人民卫生出版社,2003.740-748.
  • 2IsaacM.Where are we going with SSRIs[J].Eur neuropsychopharmacol,1999,3:201

共引文献21

同被引文献32

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部